BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 15020264)

  • 21. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
    Cartron JP; Elion J
    Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.
    Wang WC; Helms RW; Lynn HS; Redding-Lallinger R; Gee BE; Ohene-Frempong K; Smith-Whitley K; Waclawiw MA; Vichinsky EP; Styles LA; Ware RE; Kinney TR
    J Pediatr; 2002 Feb; 140(2):225-9. PubMed ID: 11865275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea and new agents for the treatment of sickle cell disease.
    Rodgers GP
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A; Gumruk F; Gurgey A
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sickle cell patients find a brand New World.
    Noonan SS
    N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models.
    Pino P; Taoufiq Z; Brun M; Tefit M; Franetich JF; Ciceron L; Krishnamoorthy R; Mazier D
    Parasite Immunol; 2006 Dec; 28(12):675-80. PubMed ID: 17096647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
    Mellouli F; Bejaoui M
    Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
    Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
    J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
    Gerotziafas GT; Van Dreden P; Chaari M; Galea V; Khaterchi A; Lionnet F; Stankovic-Stojanovic K; Blanc-Brude O; Woodhams B; Maier-Redelsperger M; Girot R; Hatmi M; Elalamy I
    Thromb Haemost; 2012 Jun; 107(6):1044-52. PubMed ID: 22535498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia.
    Lemonne N; Charlot K; Waltz X; Ballas SK; Lamarre Y; Lee K; Hierso R; Connes C; Etienne-Julan M; Romana M; Connes P
    Haematologica; 2015 Oct; 100(10):e383-6. PubMed ID: 26137960
    [No Abstract]   [Full Text] [Related]  

  • 36. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
    Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
    Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
    Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
    Conran N; Fattori A; Saad ST; Costa FF
    Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Terrin ML; Moore RD; Dover GJ; Barton FB; Eckert SV; McMahon RP; Bonds DR
    N Engl J Med; 1995 May; 332(20):1317-22. PubMed ID: 7715639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients.
    Pallis FR; Conran N; Fertrin KY; Olalla Saad ST; Costa FF; Franco-Penteado CF
    Br J Haematol; 2014 Jan; 164(2):286-95. PubMed ID: 24383847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.